Overcoming Cancers Resistant to Her 2 Antibodies

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Therefore, the use of various immunosensitizing agents to reverse resistance has been considered and this book discusses each of them in depth, such as Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to HER-2 antibodies. Provides a general summary of various sensitizing agents that can work effectively when used in combination with anti-HER2 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to antibody treatment Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Produk Detail:

  • Author : Benjamin Bonavida
  • Publisher : Sensitizing Agents for Cancer
  • Pages : 250 pages
  • ISBN : 9780128164082
  • Rating : 4/5 from 21 reviews
CLICK HERE TO GET THIS BOOKOvercoming Cancers Resistant to Her 2 Antibodies

Overcoming Cancers Resistant to Her-2 Antibodies

Overcoming Cancers Resistant to Her-2 Antibodies
  • Author : Benjamin Bonavida
  • Publisher : Sensitizing Agents for Cancer
  • Release : 15 December 2019
GET THIS BOOKOvercoming Cancers Resistant to Her-2 Antibodies

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. It also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies.There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding

Targeted Therapies in Breast Cancer

Targeted Therapies in Breast Cancer
  • Author : George W. Sledge, Jr.,Jose Baselga
  • Publisher : Unknown Publisher
  • Release : 15 April 2013
GET THIS BOOKTargeted Therapies in Breast Cancer

This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.

Resistance to Immunotherapeutic Antibodies in Cancer

Resistance to Immunotherapeutic Antibodies in Cancer
  • Author : Benjamin Bonavida
  • Publisher : Springer Science & Business Media
  • Release : 04 August 2013
GET THIS BOOKResistance to Immunotherapeutic Antibodies in Cancer

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies
  • Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
  • Publisher : Springer
  • Release : 15 July 2019
GET THIS BOOKCurrent Applications for Overcoming Resistance to Targeted Therapies

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
  • Author : Goli Samimi,Christina Annunziata
  • Publisher : Academic Press
  • Release : 06 November 2020
GET THIS BOOKOvercoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment.

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer
  • Author : Sara Hurvitz,Kelly McCann
  • Publisher : Elsevier Health Sciences
  • Release : 26 July 2018
GET THIS BOOKHER2-Positive Breast Cancer

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
  • Author : Andrew Freywald,Franco Vizeacoumar
  • Publisher : Academic Press
  • Release : 04 December 2020
GET THIS BOOKBiological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it

Her-2

Her-2
  • Author : Robert Bazell
  • Publisher : Random House
  • Release : 27 April 2011
GET THIS BOOKHer-2

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation,

Breast Cancer Chemosensitivity

Breast Cancer Chemosensitivity
  • Author : Dihua Yu,Mien-Chie Hung
  • Publisher : Springer Science & Business Media
  • Release : 30 December 2009
GET THIS BOOKBreast Cancer Chemosensitivity

In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem, the book then focuses on the latest findings of molecular mechanisms of drug resistance. Coverage provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. It allows those who are interested in breast cancer

Resistance to Tyrosine Kinase Inhibitors

Resistance to Tyrosine Kinase Inhibitors
  • Author : Daniele Focosi
  • Publisher : Springer
  • Release : 07 November 2016
GET THIS BOOKResistance to Tyrosine Kinase Inhibitors

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

Investigating Novel Therapies for Breast Cancers Resistant to Trastuzumab
  • Author : Banujan Balachandran
  • Publisher : Unknown Publisher
  • Release : 19 June 2021
GET THIS BOOKInvestigating Novel Therapies for Breast Cancers Resistant to Trastuzumab

"Approximately 20% of all metastatic breast cancers overexpress the HER-2 receptor, a cell surface-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab, a humanized monoclonal antibody binding to the extracellular domain of HER-2, has proven to be a beneficial treatment for patients diagnosed as HER-2+ but continues to have limitations. With low response rates for patients when administered alone and for patients having received prior chemotherapy, the true potential of trastuzumab seems to arrive only through combination

Breast Cancer

Breast Cancer
  • Author : Mehmet Gunduz,Esra Gunduz
  • Publisher : BoD – Books on Demand
  • Release : 30 November 2011
GET THIS BOOKBreast Cancer

Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as

Colorectal Cancer

Colorectal Cancer
  • Author : Jindong Chen
  • Publisher : BoD – Books on Demand
  • Release : 16 May 2018
GET THIS BOOKColorectal Cancer

With international experts sharing their experience and knowledge on these different aspects in the management of colorectal cancer, this book has this opportunity to offer all physicians treating colorectal cancer, as well as researchers, updated information concerning the biology, diagnosis, screening, and treatment of colorectal carcinoma. This book provides a detailed evaluation of diagnostic modalities, in-depth analysis of screening for colorectal cancer, recent advances in treatment, and principles and trends in the management of colorectal cancer. This updated knowledge will